If you have access to the internet you might try the Diabetes UK website which provides a huge amount of information which may help answer your dietary queries.

Good advice on diet is essential in the proper care of diabetes and it should be tailored to individual requirements. You may therefore prefer to arrange to see a State Registered Dietitian through your hospital or your GP. Most hospitals have a State Registered Dietitian attached to the diabetes clinic, and you could arrange to see them at your next clinic visit. Some general practitioners organise their own diabetes clinics, and may arrange for a dietitian to visit this clinic. Many nurses and health visitors who are specially trained in diabetes will also be able to provide good basic dietary advice.

I am a Hindu and have been diagnosed with Type 2 diabetes. Are there any specific dietary restrictions?

No, there are no specific dietary restrictions, except for keeping the amount of carbohydrates in your diet under control. You may need to eat smaller portions of rice, or fewer chapattis or rotis with your main meal, but there needs to be no change to the amount of meat or vegetables in your diet.

Avoid sweet preparations, especially gullab jamun, jillabee and similar sweets which have a very high sugar content, as these may cause your blood sugar to rise very quickly. Do not yield to temptation during religious festivals or at weddings when you will be offered a wide variety of sweets. Exercise regularly and keep your weight under control, as advised by your GP or practice nurse.

Subscribe to our Facebook Health and Care Canadian page https://www.facebook.com/pages/Health-and-Care-Info/963724666987760

I am a Jew and I have Type 2 diabetes. Can you advise me on how best to cope with eating on the Sabbath?

Eating on the Sabbath (Shabbot) and holidays should be a happy time for families to gather together and celebrate. You will need to pay particular attention to the carbohydrate content of your meals and avoid food that is likely to increase your blood sugar level.

Jewish Law (Torah) restricts the testing of blood sugars on the Sabbath and festival days. So it is best to test either before or after the main meal the day before. This activity will be best carried out at a time when there are no guests around.

The Jewish Diabetic Association has a very active website which contains a number of articles and useful links on the glycaemic index of foods, recipes and healthy eating in the section on enlightened kosher cooking. We strongly recommend David Mendosa’s website: www.mendosa.com which contains helpful information presented in an upbeat style.

In conclusion, the BAP-65 system correlates well with the need for MV, hospital mortality, LOS, and cost in patients diagnosed with an AECOPD in a graded fashion. Although no clinical decision rule is infallible, and clinicians must always apply their best judgment, application of the BAP-65 may facilitate accurate risk stratification for both clinical and resource use outcomes, as well as aid in triage decision making in AECOPD.

Background: Patients with COPD experience more frequent exacerbations in the winter. However, little is known about the impact of the seasons on exacerbation characteristics.

Methods: Between November 1, 1995, and November 1, 2009, 307 patients in the London COPD cohort (196 men; age, mean, 68.1 years [SD, 8.4]; FEV^ mean, 1.12 L [SD, 0.46]; FEV^ mean, % predicted, 44.4% [SD, 16.1]) recorded their increase in daily symptoms and time outdoors for a median of 1,021 days (interquartile range [IQR], 631-1,576). Exacerbation was identified as > 2 consecutive days with an increase in two different symptoms.

Results: There were 1,052 exacerbations in the cold seasons (November to February), of which 42.5% and 50.6% were patients who had coryzal and cough symptoms, respectively, compared with 676 exacerbations in the warm seasons (May to August), of which 31.4% and 45.4% were in patients who had coryzal and cough symptoms, respectively (P < .05). The exacerbation recovery period was longer in the cold seasons (10 days; IQR, 6-19) compared with the warm seasons (9 days; IQR, 5-16; P < .005). The decrease in outdoor activity during exacerbation, relative to a pre-exacerbation period (-14 to —8 days), was greater in the cold seasons ( — 0.50 h/d; IQR, —1.1 to 0) than in the warm seasons ( — 0.26 h/d; IQR, —0.88 to 0.18; P = .048). In the cold seasons, 8.4% of exacerbations resulted in patients who were hospitalized, compared with 4.6% of exacerbations in the warm seasons (P = .005).

Respiratory viruses are more prevalent in the winter of temperate countries. There are also many more deaths, hospital admissions, and general practitioner consultations for COPD in winter, along with poorer health-related quality of life and worse anxiety and depression scores. This increase in mortality and morbidity places a heavy burden on health and care services in winter.

www.viagraaustraliaau.com – Australia Pharmacy. Cheap and safe medications.

Exacerbations are more frequent in the winter, but it is not known whether their severity is worse. In this study, we examine whether symptom composition, symptom duration (recovery), hospitalization rates, and impact on outdoor activity vary between warm and cold seasons. A greater understanding of the nature of winter exacerbations could help reduce hospital admissions and inform preventative strategies. The information could be also important for the design, analysis, and interpretation of data from interventional clinical trials, and relevant to the evaluation of COPD admission health forecasting and alert services. Some of the results of these studies have been previously reported in the form of an abstract at the 2009 European Respiratory Society meeting in Vienna, Australian Medicine website.

Materials and Methods

Patients

This study involved 307 patients with COPD enrolled in the London COPD cohort and included their contributing data from at least 1 year between November 1, 1995, and November 1, 2009. The patients and exacerbations have been the subject of previous publications, but the current analysis and its interpretation are, to our knowledge, completely novel. COPD was defined as an FEVi < 80%, predicted from age, height, and sex, and FEV/FVC < 70%.

Cysteinyl leukotrienes (LTC4, LTD4, LTE4) are lipid mediators synthesized from arachidonic acid. Montelukast has been shown to inhibit the increase of ASM mass, goblet cell metaplasia, and epithelial cell hyperplasia in a rat model of allergic asthma. Exogenous administration of LTD4 reproduces these effects. Montelukast inhibits but also reverses the increase of ASM mass and subepithelial fibrosis in a mouse asthma model. No studies of the effect of leukotriene modifiers have been performed in human subjects with respect to airway remodeling.

Somewhat surprisingly, tiotropium, a long-acting muscarinic receptor antagonist, inhibited the increase of ASM mass and goblet cell metaplasia in allergen-challenged guinea pigs and mice. In animal COPD models, tiotropium has been shown to inhibit goblet cell metaplasia, mucin production, and vascular remodeling but to have no effect on airspace enlargement. Although bronchoconstriction per se may release growth-promoting molecules from airway epithelium, it is not clear whether the effects of tiotropium are mediated by affecting airway mechanics or through predominantly biochemical processes. The effect of tiotropium on airway remodeling has not been evaluated in human subjects.

T helper (Th) lymphocytes are present in airways of patients with asthma and synthesize and release the signature cytokines IL-4, IL-5, and IL-13. They modulate the airway inflammatory response, causing eosinophilia, enhancing IgE synthesis, and promoting airway hyperresponsiveness. Animal experiments have implicated IL-13 in goblet cell metaplasia and subepithelial collagen deposition using IL-13-deficient mice and by administration of IL-13 itself or of molecules neutralizing its effects. IL-13 causes up-regulation of contractile processes in ASMC but may not influence ASM mass. However, clinical trials have shown little or no effect of anti-IL-13 antibody therapy on lung function, which may or may not be a suitable surrogate for airway remodeling.

• restore libido and improve erectile function;
• stimulate male hair growth;
• increase muscle mass and strength;
• increase BMD, potentially reducing the risk of fractures;
• improve energy, mood, and motivation;
• increase hematocrit into the normal adult male range.
•  Viagra Online Australia

In most men with ED, T treatment alone is insufficient to restore complete erectile function and permit satisfactory intercourse. Because spermatogenesis requires high local T concentrations that cannot be achieved by exogenous androgen administration, T replacement therapy does not stimulate sperm production and testis size, nor does it restore fertility. Treatment of infertility in hypogonadal men is usually only possible in men with secondary hypogonadism and gonadotropin deficiency, using gonadotropin or gonadotropin-releasing hormone (GnRH) therapy.

The normal “physiological” range of serum T concentrations in adults is broad and usually established in healthy young men. In young hypogonadal men, T treatment produces beneficial clinical effects when serum T concentrations are increased into this normal range. With increasing age, serum T levels decline gradually and progressively, but the physiological significance of this decline is not clear. Initial studies in older hypogonadal men have also demonstrated some beneficial effects of T treatment that increase serum T levels into the normal range. Therefore, the goal of T treatment of male hypogonadism, irrespective of age, is to restore serum T concentrations to within the normal adult range.
Canadian health and care mall
An important consideration in the clinical use of T therapy is the dose–response effect of T on different target organs. Recent studies suggest that some actions of T demonstrate continuous dose-response effects as T levels are increased from below normal to within and above the physiological range—e.g., muscle mass. In contrast, other T actions exhibit threshold effects—e.g., libido—that are stimulated near maximal levels at relatively low T concentrations. In some patients—e.g., elderly men with severe prostate disease—low-dose T supplementation may be more prudent than full T replacement. Although not demonstrated in clinical trials, low doses of T may be sufficient to induce some beneficial effects such as the stimulation of libido and, to a limited extent, anabolic actions on muscle and bone, while minimizing adverse stimulatory effects on prostate growth.

Males with prepubertal T deficiency usually present as adolescents or young adults with delayed puberty, manifesting varying degrees of eunuchoidism characterized by a small penis, a poorly developed scrotum, small testes (< 5 mL), and prostate, lack of male hair growth (facial, chest, axillary, pubic, perianal, and extremity hair), body habitus characterized by long arms and legs relative to height, poorly developed muscle mass, prepubertal fat distribution; reduced bone mass, high-pitched voice, poor libido (sexual interest and desire) and sexual function, reduced energy, mood alterations and lack of motivation, benign breast enlargement (gynecomastia), failure to produce an ejaculate (aspermia) and initiate spermatogenesis (azoospermia), and a relatively low hematocrit (in the female range).

Therefore, in boys with delayed puberty, the therapeutic goals of T treatment are to promote:

• the development of secondary sexual characteristics, including growth of the penis, the scrotum, and a male hair pattern;
• stimulate the acquisition of peak bone mass, long bone growth, and eventual closure of epiphyses [through the
• aromatization of T to estradiol (E2)] without compromising adult height;
• increase muscle mass and strength and reduce fat mass;
• induce laryngeal enlargement and deepening of the voice;
• stimulate libido and erections;
• improve energy, mood, and motivation;
• increase red-blood-cell production into the normal adult male range.

By stimulating accessory sex glands (seminal vesicles and prostate), T treatment stimulates seminal fluid production and an increase in ejaculate volume, but it does not stimulate sperm production sufficient for induction of fertility. Because the most common cause of delayed puberty is not pathological but rather constitutional, T therapy in boys with delayed puberty is usually intermittent and continued only until spontaneous puberty occurs.

Unless severe, T deficiency in adult males is usually more difficult to diagnose because the clinical manifestations are often subtle and attributable to other causes. T-deficient men usually present with poor sexual performance manifested by reduced libido and erectile dysfunction – viagra in canada (ED) as their major complaints, although T deficiency is not the primary etiology in the majority of men with ED.

• They may also manifest gynecomastia;
• infertility due to impaired sperm production;
• diminished chest, axillary, and pubic hair;
• decreased muscle bulk and strength;
• low BMD that may result in osteopenia or osteoporosis;
• low energy and motivation;
• irritability and a depressed mood;
• a mild hypoproliferative anemia in the normal female range – female viagra australian.

Testis size is usually normal but may be small (< 15 mL) in men with profound reductions in sperm production. Hot flushes may occur in men with a rapid onset of severe androgen deficiency.

]]> http://www.diseasesjournal.com/therapeutic-goals-of-t-treatment.html/feed 0 http://www.diseasesjournal.com/inhibitory-effects-of-irf-3er-dimerization-on-hcv-jfh-1-virus-replication-part-2.html http://www.diseasesjournal.com/inhibitory-effects-of-irf-3er-dimerization-on-hcv-jfh-1-virus-replication-part-2.html#comments Sat, 29 Dec 2012 20:17:17 +0000 http://www.diseasesjournal.com/?p=379 Host immunity, including innate immunity and adaptive immunity, is an important and complicated system dedicated to the task of defending the host from microbial infection and cancer development. Innate immunity provides an immediate (first line) reply to a microbial infection, specifically for viral infections, while also controlling the later antigen-specific adaptive response. A key aspect of the antiviral innate immune response is the synthesis and secretion of type I INFs (α and β), which exhibit antiviral, anti-proliferative, and immunomodulatory functions. Two key steps are required to elicit an effective antiviral innate immune response: a. detection of the invading virus by immune system receptors; b. initiation of protein signaling cascades that regulate the synthesis of IFNs. Viruses are highly infectious pathogens that depend on host cellular machinery for survival and replication. Most viral infections, like the common cold caused by Rhinoviruses, are efficiently resolved by the host innate and adaptive immune system. For other viral infections, such as chronic hepatitis B or C viral infection, the host innate and adaptive immunity response is unable to clear them effectively and they become persistent infections. Several families of PPRs have been demonstrated to inspect the cellular micro-environment for microbial infection to target the pathogen-associated molecular patterns (PAMPs), a conserved structural moiety essential for microbial survival. Toll-like receptors (TLRs 3, 4, 7, 8, and 9) in addition to RIG-I are major PPRs that recognize different types of virally-derived nucleic acids or intracellular dsRNA to initiate signaling cascades leading to production of type I IFNs (details in reviews). The mechanisms by which different viruses induce a unique IFN-mediated antiviral response appear to require selective activation of members of the IRF family of proteins (IRF-1 to IRF-9). Thus far, IRF-3 and IRF-7 have been shown to be major regulators of IFN gene expression.

The type I IFNs, represented by multiple subtypes of IFN-α in addition to one subtype IFN-β, are key cytokines in this process, mounting an immediate antiviral response as well as adaptive immunity. IFN-mediated anti-viral effects are carried out using different mechanisms that are dependent on the type of viral infection, but these anti-viral effects are all dependent on IRF-3 activation. Activation of IRF-3 proteins appears to recruit the Tank Binding Kinase 1 (TBK1) and inhibitor of IκB-related kinase epsilon (IKKε) through their interaction with the RIG-I RNA helicase, resulting in phosphorylation of IRF-3, its dimerization, nuclear translocation, and transcriptional activation through binding to IFN-stimulated response elements (ISREs). Activated IRF-3 interacts with nuclear factor-κB (NF-κB) and transcriptional factor-2/c-Jun to form a transcriptionally active enhanceosome complex on IFNA1 and IFNB gene promoters.

In our studies, we utilized an IRF-3/mouse ER fusion protein expressing plasmid in order to achieve IRF-3ER activation in a cytokine/receptor-independent fashion. Our results demonstrated that IRF-3ER homodimers triggered the downstream pathways to produce IFN-α and IFN-β (Figure 2A and 2B). The anti-HCV effects, induced by 4-HT in Huh7.5-IRF3ER cells, were achieved by decreasing HCV RNA replication and HCV IRES-mediated translation. This is consistent with our previous studies which achieved activation of STAT1/and STAT3/mouse ER fusion proteins. Activation of the IRF-3ER fusion protein by 4-HT treatment provides strong evidence that this is necessary and sufficient to increase IFN-α and IFN-β expression in Huh7.5-IRF3ER cells. Our data showing that IRF-3ER activation triggers the downstream pathway, activating the JAK/STAT pathway and regulating ISG expression. Detection of p-STAT1 (S727) and p-STAT3 (Y705) in Huh7.5-IRF3ER cells provides a strong evidence for activation of Jak/STATs pathway by IFNs. Although the mechanism of IFN action against HCV replication has not been well defined, recent studies suggest that IFNs have a great impact on HCV replication by interrupting HCV IRES-mediated translation. Clinical data confirmed these findings in a study of HCV IRES-mediated translation in chronic HCV patients receiving IFN treatment, in which the efficiency of HCV IRES-mediated translation was reduced in IFN-treated HCV patients. In our study, the inhibitory effects of HCV RNA replication and HCV IRES-mediated translation were confirmed in Huh7.5-IRF3ER cells after treatment with 4-HT.

Expression of ISGs in Huh7.5-IRF3ER cells

All of the IFN types activate JAK/STAT pathways, regulating the expression of over 300 ISGs in order to achieve their anti-viral effects. In our previous studies, we demonstrated a novel pathway by which IFN inhibits HCV IRES-mediated translation through up-regulating 1-8U gene expression and down-regulating expression of the hnRNP M gene (unpublished data). In this study, we measured 1-8U and hnRNP M expression in Huh7.5-IRF3ER cells with and without 4-HT treatment. The 1-8U protein was detected by Western blotting and was up-regulated in Huh7.5-IRF3ER cells after 4-HT treatment. Due to auto-dimerization of IRF-3ER fusion protein in Huh7.5-IRF3ER cells, the fold-induction of 1-8U protein is not as robust as described in our previous report in which the STAT1 gene was activated. Real-time quantitative reverse-transcription PCR was used to detect and measure hnRNP M mRNA expression in Huh7.5-IRF3ER cells. After 4-HT treatment, hnRNP M mRNA levels were down-regulated in a time-dependent fashion. This data confirms that activation of the IRF-3ER fusion protein triggers a cellular anti-HCV state through inducing IFNs production and regulating ISG expression.

Expression of IFNs after activation of the IRF-3ER fusion protein

Due to deficient RIG-I gene function in Huh 7.5 cells, virus infection will not lead to IRF-3 activation and IFN secretion. This phenomenon allows us to study IRF-3 gene function against HCV infection by establishing a stable Huh7.5-IRF3ER cell line. Fusion proteins of STAT1 and STAT3 with the mouse estrogen receptor provided a useful means to study dimerization of those proteins and resulting in anti-HCV status. In this study, the IRF-3 gene was fused with same C-terminal sequences of mouse estrogen receptor as reported for inducing IRF-3ER dimerization by 4-HT treatment. Expression of type I IFNs (α and β) was examined after 4-HT treatment by real-time PCR. IFN-α and IFN-β increased and peaked 24 hours after 4-HT induction. To further demonstrate the biological activities of IFN-α and IFN-β after IRF-3ER dimerization, Western blotting was used to detect phosphorylated STAT1 and STAT3. In Figure 3A, phosphorylated STAT1 was detected with an antibody against STAT1 (S727) in Huh 7.5 and Huh7.5-IRF3ER cells. Different amounts of phosphorylated STAT1 were observed in both Huh 7.5 cells and Huh7.5-IRF3ER cells. There were no appreciable time-dependent differences in phosphorylated STAT1 in Huh7.5-IRF3ER cells with or without 4-HT treatment. This observation is consistent with the auto-dimerization of IRF-3ER fusion protein to produce IFNs. In Figure 3B, phosphorylated STAT3 was examined; there was no difference between Huh 7.5, Huh7.5-IRF3ER cells with or without 4-HT treatment. This phenomenon could be explained by the constant activation of IRF-7 to induce expression of IFN-α which activates the type I IFN pathway through STAT3 phosphorylation. Total STAT1 and STAT3 proteins was used as internal controls and demonstrated no differences with or without 4-HT treatment on Huh7.5-IRF3ER cells or Huh 7.5 cells.

Detection of IFN-α and IFN-β in Huh7.5-IRF3ER cells

Huh7.5-IRF3ER cells were treated with 4-HT for 72, 48, and 24 hours prior to collecting cellular lysates. Control is Huh7.5-IRF3ER cells that did not receive 4-HT treatment for 72 hours. Total cellular RNA was isolated for detecting IFN-α or IFN-β RNA by real-time PCR.

Real-Time PCR assay

Total cellular RNA was isolated from infected Huh7.5-IRF3ER monolayers by Trizol (Invitrogen). First-strand cDNA were synthesized from 1 μg total cellular RNA by reverse transcription (20 μl of reaction volume). Superscript II (200 U reverse transcriptase per reaction) and a RT-PCR kit (Invitrogen) was used to prime with oligo (dT) 12-18 for first-strand synthesis according to the manufacturer’s instructions. Taqman primers were obtained from Applied BioSystems. Reactions were conducted in a 96-well MyiQ cycler (Bio-Rad, Hercules, CA). Fluorescence was monitored during every PCR cycle at the annealing step. The primers for HCV JFH-1 are: forward, 5′-CGGAATTGCCGGGAAGAC-3′; reverse, 5′-CAAATGGCCGGGCATAG AG-3′; FAM probe, 5′-CTTTCTTGGATAAACCC-3′. The primers for IFN-α are: forward, 5′- GGGATGAGGACCTCCTAGACAAATT-3′; reverse, 5′- ACACAGGCTTCCAAGTCA TTC-AG-3′; FAM probe, 5′- CTGCACCGAACTCTAC-3′. The primers for IFN-β are: forward, 5′-TGGCTGGAATGAGACTATTGTTGAG-3′; reverse, 5′-CAGGACTGTCTTCA GATGG-TTTATCT-3′; FAM probe, 5′-CCTCCTGGCTAATGTC-3′. GADPH primers were purchased from the Applied Biosystems. PCR was performed with the following conditions: 50°C, 2 min; 95°C, 10 min; (95°C, 15s; 60°C, 1 min) for 40 cycles. Relative RNA level indicates statistical quantification of altered RNA levels from these cellular lysates with different primers. Samples were run in triplicate and the results were analyzed using the Bio-Rad iQ5 software; means ± the standard error of the mean are shown.

Luciferase assays

Huh7.5-IRF3ER cells were cultured in 6-well plates and transfected with the plasmid pRL-HL and lipofectamine 2000 (Invitrogen). After 24-hours of transfection, Huh7.5-IRF3ER cells were treated with 4-HT for 96, 72, and 48 hours prior to preparing cell lysates. Control Huh7.5-IRF3ER cells were incubated for 96 hours in the absence of 4-HT. All samples were analyzed for luciferase activity using the Dual-Luciferase Reporter Assay System Kit (Promega, Madison, WI) in triplicate. The translation efficiency was calculated as a proportion of control (100%).

Statistical analysis

Different cellular lysates were collected for analysis of luciferase activity or relative RNA level from Huh7.5-IRF3ER cells with special treatment. Results of these studies are expressed as means ± standard deviation (SD).